- Horizon Pharam (NASDAQ:HZNP) acquires privately held Crealta Holdings LLC for $510M in cash. The Glendale, WI-based firm's lead product is Krystexxa (pegloticase), a PEGylated uric acid-specific enzyme indicated for the treatment of chronic gout in adults who fail to respond to conventional therapy. The FDA cleared the product in 2010.
- The deal should add $70M - 80M to Horizon's top line and $45M - 50M to non-GAAP EBITDA in the first 12 months following the close, expected to happen in Q1.
- Horizon will host a conference call this morning at 8:00 am ET to discuss the transaction.
Horizon Pharma buys Crealta Holdings for $510M in cash
Recommended For You
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| HZNP | - | - |
| Horizon Therapeutics Public Limited Company | ||